Cogent Biosciences Inc
COGT
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
97.3% downsideOvervalued by 97.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.97 Billion |
|---|---|
| Enterprise Value | $5.97 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.55 |
| Beta | 0.37 |
| Outstanding Shares | 67,414,000 |
Return
| Return on Equity | -58.30% |
|---|---|
| Return on Assets | -39.24% |
| Return on Invested Capital | -43.44% |
Valuation & Multiples
| P/E Ratio | -6.65 |
|---|---|
| PEG | -18.88 |
| Price to Sales | - |
| Price to Book Ratio | 3.58 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -16.27 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5930▼ 22.12% |
|---|---|
| Total Calls | 865,300▲ 63.11% |
| Total Puts | 513,100▲ 18.80% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 275.64%▲ 18.12% |
|---|---|
| Total Invested | $7.17B▲ 15.94% |
| Investors Holding | 316▲ 41.00% |
ESG Score
No data
About Cogent Biosciences Inc
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently ...
Relevant Senate Committees
This committee provides crucial analysis and 'revenue estimates' for all tax legislation, directly influencing corporate tax structures and capital investment incentives for companies like Cogent.
This powerful committee controls taxation, trade, and entitlement spending (e.g., Medicare pricing), which are fundamental drivers of corporate valuation and revenue for pharmaceutical companies.
This committee controls the allocation of discretionary federal spending for health and research agencies (e.g., FDA, NIH), directly impacting the regulatory environment and funding for biotech R&D.
This committee directly regulates the FDA and NIH, which are critical for drug approval, clinical trials, and research funding, directly impacting Cogent Biosciences' core business.
This committee's jurisdiction over intellectual property and antitrust laws is critical for a biotech company, influencing patent protection and potential M&A activities.
This committee influences R&D grants and capital flow for small and innovative enterprises (SBIR programs), which are crucial funding sources for biotechnology companies like Cogent.
Its funding decisions for the Department of Veterans Affairs directly impact government healthcare contractors and could influence procurement and reimbursement for Cogent's therapies.